A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
assessed every 9 weeks (after every 3rd cycle) until progression
No
Clinical Trials
Study Director
Hoffmann-La Roche
Spain: Ministry of Health
MO22223
NCT00929240
July 2009
August 2013
Name | Location |
---|